GOLD COPD Report 2025: Key Spirometry and Drug Updates
Nov 22, 2024 · The 2025 GOLD COPD report, titled “Global Strategy for Prevention, Diagnosis and Management of COPD: 2025 Report,” can now be downloaded from the GOLD website, along with a pocket guide to the report and the “2025 …
GINA 2024 Asthma Update: Revised Recommendations on …
Jun 28, 2024 · The GINA 2024 asthma update includes new guidance on medications, monitoring, treatment goals, remission, cough variant asthma, children, and more.
Restrictive Lung Diseases | Diagnosis & Disease Information
May 29, 2024 · Restrictive lung diseases are respiratory disorders marked by diminished lung capacity stemming from a wide range of underlying factors, including changes in lung parenchyma or conditions that affect the pleura, chest wall, or neuromuscular system. 1 Restrictive lung diseases can be classified as pulmonary parenchyma diseases (intrinsic causes) or extrapulmonary diseases (extrinsic causes ...
Diagnosis & Disease Information - Pulmonology Advisor
Apr 5, 2024 · Hemothorax is a collection of blood in the pleural space that is often the result of a traumatic injury. 1 Symptoms of hemothorax include chest pain and shortness of breath. Potential late complications include empyema and fibrothorax, which can lead to lung entrapment or collapse and respiratory failure. 1 Rapid evaluation and diagnosis are crucial for symptom relief and optimal patient outcomes.
2024 GOLD Report Reflects New Research on COPD Management
Dec 8, 2023 · The 2024 GOLD Report, “Global Strategy for Prevention Diagnosis and Management of COPD,” not only includes guideline updates that reflect the latest research on chronic obstructive pulmonary disease (COPD); it also reflects some shifts in thinking about what’s important in COPD treatment, according to Claus Vogelmeier, MD, a lead report author and science committee chair for the Global ...
Dupixent Approved as Add-On Maintenance Therapy in COPD
Oct 1, 2024 · The Food and Drug Administration (FDA) has approved Dupixent (dupilumab) as an add-on maintenance therapy for adults with inadequately controlled chronic obstructive pulmonary disease (COPD) and an eosinophilic phenotype.. The approval was supported by data from the randomized, double-blind, multicenter, parallel-group, placebo-controlled, phase 3 trials BOREAS (ClinicalTrials.gov Identifier ...
Treatment Options for Methicillin-Resistant Staphylococcus Aureus ...
Jun 19, 2019 · Evidence for the treatment of methicillin-resistant Staphylococcus aureus (MRSA) pneumonia with trimethoprim-sulfamethoxazole (TMP-SMX), clindamycin, doxycycline, or minocycline was found to be based on limited data, according to a systematic review published in the Annals of Pharmacotherapy.. Currently, the Infectious Disease Society of America (IDSA) recommends vancomycin and linezolid for ...
Updated CHEST Guidelines on Antithrombotic Therapy in Venous ...
Jan 21, 2022 · Updates to the American College of Chest Physicians (CHEST) clinical practice guideline on antithrombotic therapy in venous thromboembolism (VTE) include recommendations on several Population, Intervention, Comparator, Outcome (PICO) questions covering a wide spectrum of VTE-related antithrombotic management scenarios.
Diagnosis & Disease Information - Pulmonology Advisor
Apr 12, 2024 · Pneumonitis refers to inflammation or irritation of the lungs that is triggered by allergens, environmental irritants, radiation therapy for cancer, and certain medications. 1 Patients with pneumonitis experience shortness of breath, a dry cough, and chest pain. In many cases, these symptoms resolve by limiting exposure to the trigger.
HARMONi-2: Ivonescimab Outperforms Pembrolizumab in …
Sep 10, 2024 · Ivonescimab improved progression-free survival (PFS) when compared to pembrolizumab as first-line therapy in patients with advanced non-small cell lung cancer (NSCLC) in the phase 3 HARMONi-2 trial.. These are the first randomized, phase 3 data to demonstrate a clinically significant improvement in efficacy with a novel drug over pembrolizumab in advanced NSCLC, said Caicun Zhou, MD, PhD, of ...